Total Payments
$91,294
2024 Payments
$486.85
Companies
57
Transactions
802
Medicare Patients
8,832
Medicare Billing
$1.1M
Payment Breakdown by Category
Other$60,300 (66.1%)
Food & Beverage$18,106 (19.8%)
Travel$7,380 (8.1%)
Consulting$5,500 (6.0%)
Education$7.68 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $52,300 | 19 | 57.3% |
| Food and Beverage | $18,106 | 737 | 19.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,000 | 6 | 8.8% |
| Travel and Lodging | $7,380 | 36 | 8.1% |
| Consulting Fee | $5,500 | 1 | 6.0% |
| Education | $7.68 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $61,301 | 150 | $0 (2024) |
| Depomed, Inc. | $9,399 | 37 | $0 (2017) |
| US WorldMeds, LLC | $6,480 | 12 | $0 (2019) |
| Abbott Laboratories | $3,208 | 117 | $0 (2024) |
| Collegium Pharmaceutical, Inc. | $1,086 | 67 | $0 (2024) |
| PFIZER INC. | $875.99 | 78 | $0 (2019) |
| Relievant Medsystems, Inc. | $802.04 | 10 | $0 (2023) |
| Stratus Medical, LLC | $796.37 | 9 | $0 (2023) |
| Daiichi Sankyo Inc. | $760.40 | 31 | $0 (2019) |
| Genesys Orthopedics Systems, L.L.C. | $620.15 | 5 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $486.85 | 14 | Boston Scientific Corporation ($229.48) |
| 2023 | $1,474 | 65 | Relievant Medsystems, Inc. ($277.42) |
| 2022 | $3,528 | 94 | Genesys Orthopedics Systems, L.L.C. ($620.15) |
| 2021 | $2,021 | 85 | Abbott Laboratories ($842.84) |
| 2020 | $1,557 | 58 | Abbott Laboratories ($589.05) |
| 2019 | $20,941 | 110 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($19,064) |
| 2018 | $49,750 | 200 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($41,471) |
| 2017 | $11,537 | 176 | Depomed, Inc. ($9,399) |
All Payment Transactions
802 individual payment records from CMS Open Payments — Page 1 of 33
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $23.62 | General |
| Category: Gastroenterology | ||||||
| 10/30/2024 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $14.21 | General |
| Category: PAIN | ||||||
| 10/28/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $23.06 | General |
| 07/15/2024 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: PAIN | ||||||
| 04/30/2024 | Collegium Pharmaceutical, Inc. | XTAMPZA (Drug) | Food and Beverage | Cash or cash equivalent | $14.54 | General |
| Category: Opioid Analgesic | ||||||
| 04/12/2024 | Medtronic, Inc. | INTELLIS ADAPTIVESTIM (Device) | Food and Beverage | In-kind items and services | $74.04 | General |
| Category: Spinal Cord Neurostimulation | ||||||
| 04/04/2024 | Boston Scientific Corporation | Intracept (Device) | Food and Beverage | Cash or cash equivalent | $26.41 | General |
| Category: Pain | ||||||
| 03/28/2024 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: PAIN | ||||||
| 02/23/2024 | Boston Scientific Corporation | Intracept (Device) | Food and Beverage | Cash or cash equivalent | $62.45 | General |
| Category: Pain | ||||||
| 02/22/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $17.25 | General |
| Category: Opioid Analgesic | ||||||
| 02/07/2024 | Abbott Laboratories | PROCLAIM (Device) | Food and Beverage | In-kind items and services | $23.18 | General |
| Category: Neuromodulation | ||||||
| 02/05/2024 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $14.26 | General |
| Category: Opioid Analgesic | ||||||
| 01/30/2024 | Boston Scientific Corporation | Intracept (Device) | Food and Beverage | Cash or cash equivalent | $140.62 | General |
| Category: Pain | ||||||
| 01/29/2024 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: PAIN | ||||||
| 12/28/2023 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $21.38 | General |
| Category: PAIN | ||||||
| 12/21/2023 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $6.30 | General |
| Category: PAIN | ||||||
| 12/20/2023 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $18.86 | General |
| Category: Opioid Analgesic | ||||||
| 12/11/2023 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $2.63 | General |
| Category: PAIN | ||||||
| 11/30/2023 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $5.92 | General |
| Category: PAIN | ||||||
| 11/29/2023 | Collegium Pharmaceutical, Inc. | Belbuca (Drug) | Food and Beverage | Cash or cash equivalent | $14.33 | General |
| Category: Opioid Analgesic | ||||||
| 11/07/2023 | Boston Scientific Corporation | WaveWriter Alpha Prime 16 (Device) | Food and Beverage | In-kind items and services | $22.46 | General |
| Category: WaveWriter Alpha_NMD | ||||||
| 09/12/2023 | Averitas Pharma Inc. | QUTENZA (Drug) | Food and Beverage | In-kind items and services | $18.52 | General |
| Category: PAIN MANAGEMENT | ||||||
| 08/30/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | RELISTOR (Drug) | Food and Beverage | In-kind items and services | $11.58 | General |
| Category: Gastroenterology | ||||||
| 08/28/2023 | Scilex Pharmaceuticals Inc. | ZTLido (Drug) | Food and Beverage | In-kind items and services | $18.71 | General |
| Category: Analgesic | ||||||
| 08/23/2023 | Forte Bio-Pharma LLC | NALOCET (Drug), PROLATE, PROLATE | Food and Beverage | In-kind items and services | $3.05 | General |
| Category: PAIN | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 1,865 | 3,819 | $520,461 | $201,406 |
| 2022 | 32 | 3,035 | 6,023 | $939,007 | $334,618 |
| 2021 | 27 | 2,473 | 4,484 | $848,885 | $315,230 |
| 2020 | 19 | 1,459 | 3,554 | $529,675 | $215,721 |
Total Patients
8,832
Total Services
17,880
Medicare Billing
$1.1M
Procedure Codes
122
All Medicare Procedures & Services
122 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 535 | 1,034 | $222,770 | $85,160 | 38.2% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 392 | 754 | $119,460 | $45,585 | 38.2% |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 112 | 134 | $26,800 | $15,027 | 56.1% |
| 62323 | Injection of substance into lower spine canal using imaging guidance | Office | 2023 | 58 | 75 | $31,217 | $12,711 | 40.7% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 95 | 95 | $15,475 | $5,745 | 37.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 57 | 57 | $16,366 | $5,683 | 34.7% |
| 64635 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | Office | 2023 | 13 | 18 | $13,520 | $5,611 | 41.5% |
| 64493 | Injection of lower or sacral spine facet joint using imaging guidance, single level | Office | 2023 | 22 | 28 | $9,932 | $4,743 | 47.8% |
| G2011 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention, 5-14 minutes | Office | 2023 | 252 | 333 | $10,300 | $3,839 | 37.3% |
| 64636 | Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | Office | 2023 | 13 | 18 | $5,518 | $3,141 | 56.9% |
| 62321 | Injection of substance into middle or upper spine canal using imaging guidance | Office | 2023 | 12 | 14 | $5,384 | $2,594 | 48.2% |
| 64494 | Injection of lower or sacral spine facet joint using imaging guidance, second level | Office | 2023 | 21 | 27 | $4,050 | $2,584 | 63.8% |
| 64483 | Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | Office | 2023 | 14 | 15 | $5,446 | $2,384 | 43.8% |
| 27096 | Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | Office | 2023 | 18 | 20 | $4,930 | $2,200 | 44.6% |
| 62323 | Injection of substance into lower spine canal using imaging guidance | Facility | 2023 | 17 | 23 | $14,846 | $1,487 | 10.0% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 55 | 70 | $2,363 | $790.33 | 33.4% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 13 | 14 | $1,482 | $644.84 | 43.5% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 64 | 633 | $5,496 | $537.41 | 9.8% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 17 | 17 | $731.00 | $286.28 | 39.2% |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | Office | 2023 | 15 | 57 | $3,267 | $276.91 | 8.5% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 16 | 16 | $318.00 | $143.94 | 45.3% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 18 | 19 | $220.00 | $106.97 | 48.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 12 | $398.00 | $93.90 | 23.6% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 24 | 336 | $172.75 | $31.59 | 18.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 620 | 1,353 | $295,797 | $122,302 | 41.3% |
About Dr. Terrell Phillips, DO
Dr. Terrell Phillips, DO is a Specialist healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1871534024.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Terrell Phillips, DO has received a total of $91,294 in payments from pharmaceutical and medical device companies, with $486.85 received in 2024. These payments were reported across 802 transactions from 57 companies. The most common payment nature is "Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program" ($52,300).
As a Medicare-enrolled provider, Phillips has provided services to 8,832 Medicare beneficiaries, totaling 17,880 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 122 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Oklahoma City, OK
- Active Since 06/09/2006
- Last Updated 11/11/2020
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1871534024
Products in Payments
- RELISTOR (Drug) $37,427
- LUCEMYRA (Drug) $23,470
- Nucynta (Drug) $9,391
- Lucemyra/Lofexidine (Drug) $6,480
- Intracept (Device) $1,032
- Neuromodulation Dspsbls and Accs (Device) $1,017
- PROCLAIM (Device) $697.90
- Morphabond ER (Drug) $633.07
- RELISTOR ORAL (Drug) $585.12
- Proclaim DRG IPG (Device) $568.33
- Nimbus (Device) $554.74
- Amitiza (Drug) $462.02
- MOVANTIK (Drug) $431.95
- LYRICA (Drug) $410.30
- XTAMPZA (Drug) $409.25
- Proclaim Family of SCS IPGs (Device) $346.55
- Qutenza (Drug) $334.48
- COOLIEF* COOLED RADIOFREQUENCY (Device) $258.47
- Proclaim IPG (Device) $241.36
- NALOCET (Drug) $225.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Oklahoma City
Dr. James Odor, M.d, M.D
Specialist — Payments: $2.2M
Specialist $2.2M
Robert Tibbs, M.d, M.D
Specialist — Payments: $501,727
Specialist $501,727
Michael Hahn, M.d, M.D
Specialist — Payments: $271,485
Specialist $271,485
Dr. David Domek, Md, MD
Specialist — Payments: $126,624
Specialist $126,624
Robert Wienecke, M.d, M.D
Specialist — Payments: $60,200
Specialist $60,200
Mike Gonce, M.d, M.D
Specialist — Payments: $56,998
Specialist $56,998